Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate

The rVSVΔG-LASV-GPC vaccine resulted in transient local and systemic reactogenicity events but no hearing loss or serious adverse events. The vaccine had immunogenicity over a wide dose range in healthy adults in the United States and Liberia. (Funded by the Coalition for Epidemic Preparedness Innovations and the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT04794218; Pan African Clinical Trials Registry number, PACTR2021106625781067.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2025-11-05
DOI
https://doi.org/10.1056/nejmoa2501073
Citations
1
Primary Topic
Viral Infections and Outbreaks Research
Type
article
Field-Weighted Citation Impact
1.40
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate

S. A. Sewell, John McCullough, Marija Zaric, Burc Barin et al.
1 citations
New England Journal of Medicine
Viral Infections and Outbreaks Research
1.40
article

Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate

S. A. Sewell, John McCullough, Marija Zaric, Burc Barin, Michelle Engelbrecht, Julie Blie, Irina Maljkovic Berry, R. N. Varma, Arianna Marini, Devin J Hunt, Nahid Keshavarzi, Matthew Ward, Jennifer Lehrman, Johan Vekemans, Pat Fast, Dagna Laufer, Barthalomew Wilson, Peter Hayes, Kathleen A. Walker, Natalia Fernández, Elizabeth S. Higgs, Faith Sigei, Morolayo A. Ayorinde, Eddy Sayeed, Patrick Faley, Elissa Malkin, Fahimah Amini, Vincent Philiponis, Lindsey Robert Baden, Rachel Bromell, Elvis Towalid, David Fitzpatrick, Swati B. Gupta, Heejin Yun, Gaudensia Mutua, Mark Kieh, Christopher L. Parks, Hema Pindolia, Franklin Tokpah, Cecelia Wisseh, Swapnil Hadawale, Shobhna Gopal Truter, Mariette Malherbe
article en
1 citations

Abstract

The rVSVΔG-LASV-GPC vaccine resulted in transient local and systemic reactogenicity events but no hearing loss or serious adverse events. The vaccine had immunogenicity over a wide dose range in healthy adults in the United States and Liberia. (Funded by the Coalition for Epidemic Preparedness Innovations and the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT04794218; Pan African Clinical Trials Registry number, PACTR2021106625781067.).

New England Journal of MedicineVol. 393(18)
Brigham and Women's Hospital (US), International AIDS Vaccine Initiative (US), University of Liberia (LR), George Washington University (US), East–West Center (US), Emmes (United States) (US), National Institute of Allergy and Infectious Diseases (US), East West Medical Research Institute (US), George Washington University Virginia Campus (US)
Openalex Percentile: Top 15%
Viral Infections and Outbreaks Research
1.40
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.